Pyrotinib: clinical trials recruiting now

Phase breakdown

Conditions being studied

Recruiting trials involving Pyrotinib

• A Prospective, Open, Multicenter Single-arm Clinical Studie of Docetaxel, Carboplatin Combined With Inetetamab and Pyrotinib in the Treatment of Local-advanced HER2-positive Breast Cancer
  NCT06234137 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 75 Years · Sex: Female · 1 location
• Adjuvant Study of Pyrotinib in HER-2 Positive Breast Cancer
  NCT04254263 · Phase: Phase 3 · Ages: 18 Years to 70 Years · Sex: Female · 1 location
• Continuous or Intermittent Extension of Adjuvant Pyrotinib for Invasive HER2-positive Breast Cancer
  NCT05910398 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Continuous or Intermittent Pyrotinib for HER2-positive Advanced Breast Cancer
  NCT07180082 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Dalpiciclib, Anti-HER2 Therapy, and Endocrine Therapy for Hormone-Receptor-Positive, HER2-Positive Metastatic Breast Cancer
  NCT07610720 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: Female · 1 location
• Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical Trial
  NCT06278870 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: Female · 1 location
• Entinostat Plus Pyrotinib and Endocrine Therapy in Advanced Triple-Positive Breast Cancer After Trastuzumab Failure
  NCT07708194 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: Female · 1 location
• Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy
  NCT05582499 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: Female · 1 location
• Neoadjuvant Pyrotinib-to-pertuzumab in HER2+ eBC
  NCT07797218 · Phase: Phase 3 · Ages: 18 Years to 70 Years · Sex: Female · 1 location
• Neoadjuvant Trastuzumab-rezetecan Plus Pertuzumab or Nab-Paclitaxel, Carboplatin, Trastuzumab, and Pyrotinib After Suboptimal Response to Neoadjuvant Dual HER2-Targeted Therapy Combined With Chemotherapy in HER2-Positive Early Breast Cancer
  NCT07340398 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: Female · 1 location
• Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.
  NCT06563999 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Phase II Clinical Study of Pyrotinib in First-line Treatment of Primary HER2-amplified/Mutated Advanced Non-small Cell Lung Cancer
  NCT05751018 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Pyrotinib Combined With Trastuzumab for Maintenance Therapy After First-line TH (P) Therapy for HER2+ABC
  NCT06754059 · Phase: Not specified · Ages: 18 Years to 70 Years · Sex: Female · 1 location
• Pyrotinib Combined With Trastuzumab, Dalpiciclib, Letrozole Versus TCbHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HR +/HER2 + Breast Cancer
  NCT05638594 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: Female · 1 location
• Pyrotinib in Women With High-risk in Early Stage Breast Cancer
  NCT05834764 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: Female · 1 location
• RC48 Plus Bevacizumab or Pyrotinib in HER2-Positive Metastatic Breast Cancer After T-DXd Failure: A Phase II Study
  NCT07065435 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: Female · 1 location
• Real-world Study of Pyrotinib-containing Regimens of Advanced HER2-positive Breast Cancer
  NCT07600164 · Phase: Phase 4 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Study of SHR-A1811 Combined With Pyrotinib and Bevacizumab in Advanced Breast Cancer With Brain Metastasis
  NCT06718933 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• The Efficacy and Safety of Pyrotinib, Trastuzumab Combined With Taxanes in the Treatment of Trastuzumab-treated HER2+ Advanced Breast Cancer (ABC).
  NCT06217185 · Phase: Phase 4 · Ages: 18 Years to 70 Years · Sex: Female · 1 location
• ctDNA in HER2+ EBC Neoadjuvant Treatment
  NCT07335081 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: Female · 1 location

Common questions

How many recruiting trials involve Pyrotinib?

20 recruiting trials across 15 conditions.

Is this list of trials complete?

No. For the full record, search ClinicalTrials.gov.